Splash Beverage Group Rebrands as Endovia Health Sciences, Pivoting to Cannabinoid Pharmaceuticals
核心洞察
Splash Beverage Group (搜索) will change its corporate name to Endovia Health Sciences (搜索), Inc., effective August 21, 2026, adopting the new ticker symbol "EDVA."
The company's loss from continuing operations declined approximately 64% year-over-year for the first six months of 2026, from roughly $11 million to $4 million.
Endovia secured an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform originally developed for drug-resistant epilepsy (搜索).
Splash Beverage Group (搜索), Inc. (NYSE American: SBEV) announced its intention to change its corporate name to Endovia Health Sciences (搜索), Inc., effective August 21, 2026, marking the culmination of a deliberate strategic transformation from a legacy beverage business into a diversified cannabinoid health sciences platform. At that time, the Company will adopt a new ticker symbol, "EDVA," and launch EndoviaSciences.com in connection with the rebranding.
"This is much more than a name change, it is the culmination of a deliberate strategic transformation," said Brady Cobb, Interim Chief Executive Officer of the Company. "Over the past six (6) months, we have methodically repositioned the Company by acquiring differentiated pharmaceutical intellectual property, establishing international commercialization opportunities, expanding into FDA-regulated veterinary therapeutics and assembling an experienced cannabinoid pharmaceutical development team."
Financial Turnaround and Cost Reduction
The strategic pivot is underpinned by a significant improvement in the Company's financial position. For the six months ended June 30, 2026, the Company's loss from continuing operations was approximately $4 million, compared with approximately $11 million for the same period in 2025 — an improvement of approximately $7 million, or 64%. Management attributes the improvement primarily to significant cost-reduction initiatives implemented over the preceding six months as the Company shifted its focus from the sale of alcoholic beverages to the development and commercialization of cannabinoid health and wellness products.
"The first half of 2026 was about rebuilding the foundation of our Company," Cobb said. "Through disciplined execution and significant cost reductions, we expect to reduce our loss from continuing operations by approximately 64% compared with the same period last year. That progress has given us a more efficient operating platform from which to execute the strategic initiatives announced following quarter-end."
CannEpil® Licensing and Pharmaceutical Foundation
A central element of the transformation is the exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform originally developed for drug-resistant epilepsy (搜索). Entered into in early July 2026, the agreement provides the Company with a differentiated pharmaceutical asset and a foundation for future regulated therapeutic opportunities.
The Company's forward-looking disclosures note that its initial focus following the rebranding depends on its ability to maintain the license under the CannEpil license agreement, as well as its capacity to complete required studies, establish product safety and efficacy, and obtain regulatory authorization.
A Three-Pillar Growth Strategy
Endovia Health Sciences (搜索) is being built around three complementary growth engines designed to create multiple avenues for long-term growth and shareholder value. The first involves commercializing differentiated cannabinoid pharmaceutical products through international distribution, strategic partnerships, and licensing opportunities. The second focuses on advancing proprietary cannabinoid medicines through established regulatory pathways for both human and companion-animal health under FDA-regulated human and veterinary therapeutics. The third centers on developing innovative cannabinoid wellness products and beverages as regulations continue to evolve and new markets emerge.
"We believe cannabinoids represent one of the most promising frontiers in modern health sciences," Cobb continued. "Our mission is to responsibly unlock that potential through scientific innovation, strategic partnerships and disciplined execution. Every acquisition, every partnership and every investment we make is intended to strengthen our position as a leading cannabinoid health sciences company and create lasting value for patients, consumers, partners and shareholders."
Looking Ahead
The Company expects the Endovia rebrand to coincide with the launch of a new corporate website, refreshed investor materials, and a unified corporate identity reflecting its long-term strategic vision. As Endovia Health Sciences (搜索), the Company intends to continue expanding its portfolio through strategic acquisitions, commercial partnerships, regulated pharmaceutical development, and innovative consumer health products, all centered on advancing cannabinoid science through disciplined execution.
The Company's forward-looking statements caution that there can be no assurance that its goals and milestones will be achieved, that the Company or its collaborators will receive necessary regulatory approvals, or that any initiative will ultimately generate revenue. Additional risks are described in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, and the Form S-1 filed on August 7, 2026.